Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jan 2019
Randomized Controlled Trial Comparative StudyIxekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile. ⋯ Compared with ustekinumab, ixekizumab showed superior efficacy and comparable safety outcomes through 52 weeks of treatment.